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Abstract
Background and purpose: Remote ischaemic per-conditioning (RIC) is neuroprotective in 
experimental ischaemic stroke. Several neurohumoral, vascular and inflammatory media-
tors are implicated. The effect of RIC on plasma biomarkers was assessed using clinical 
data from the REmote ischaemic Conditioning After Stroke Trial (RECAST-1).
Methods: RECAST-1 was a pilot sham-controlled blinded trial in 26 patients with ischae-
mic stroke, randomized to receive four 5-min cycles of RIC within 24 h of ictus. Plasma 
taken pre-intervention, immediately post-intervention and on day 4 was analysed for ni-
tric oxide (nitrate/nitrite) using chemiluminescence and all other biomarkers by multiplex 
analysis. Biomarkers were correlated with clinical outcome (day 90 National Institutes of 
Health Stroke Scale, modified Rankin Scale, Barthel index).
Results: Remote ischaemic per-conditioning reduced serum amyloid protein (SAP) and 
tissue necrosis factor α (TNF-α) levels from pre- to post-intervention (n = 13, two-way 
ANOVA, p < 0.05). Overall (n = 26), increases in SAP pre- to post-intervention and pre-in-
tervention to day 4 were moderately correlated with worse day 90 clinical outcomes. No 
consistent significant changes over time, or by treatment, or correlations with outcome 
were seen for other biomarkers.
Conclusions: Remote ischaemic per-conditioning reduced SAP and TNF-α levels from 
pre- to post-intervention. Increases in plasma levels of SAP were associated with worse 
clinical outcomes after ischaemic stroke. Larger studies assessing biomarkers and the 
safety and efficacy of RIC in acute ischaemic stroke are warranted to further understand 
these relationships.
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INTRODUC TION
Remote ischaemic per-conditioning (RIC)—inducing ischaemia/
reperfusion distant to the brain—in experimental ischaemic stroke 
is neuroprotective [1–3]. Several neurohumoral, vascular and inflam-
matory mediators are implicated, but the underlying mechanisms 
have not been elucidated. Animal models have demonstrated several 
inflammatory, neuroprotective and vascular biomarkers that may be 
influenced by RIC, primarily in the setting of myocardial ischaemia 
and infarction [1].
There is a paucity of data on the effects of RIC on potential mecha-
nistic pathways in human patients with acute ischaemic stroke. Plasma 
heat shock proteins (HSP) 27, 60 and 70, C-reactive protein, S100-β, 
matrix metalloproteinase-9 (MMP-9), troponin T and endocannabi-
noid data have been reported in acute ischaemic stroke patients un-
dergoing RIC in the REmote ischaemic Conditioning After Stroke Trial 
(RECAST-1) [4]. There were significant increases in total and phosphor-
ylated HSP 27 in the RIC group, whilst the other biomarker levels did 
not change. Whether other inflammatory, neuroprotective or vascular 
markers are influenced by RIC in acute ischaemic stroke is unknown.
Several inflammation-related biomarkers including adipsin 
[5] α2-macroglobulin (A2 M), serum amyloid protein (SAP) [6] and 
E-selectin [7] have been associated with clinical outcome in stroke 
patients. Whether these or other elements of inflammatory path-
ways are influenced by RIC is unclear. Similarly, biomarkers contrib-
uting to vascular or neuroprotective pathways—vascular endothelial 
growth factor (VEGF) [8] von Willebrand factor (vWF) [9] or nitric 
oxide (NO)—may have roles in RIC [2,10] but have not been assessed 
in humans with acute ischaemic stroke.
Given the limited data regarding RIC and biomarkers in ischaemic 
stroke patients, in exploratory and hypothesis-generating analyses 
the effect of RIC on plasma biomarkers and the correlation of these 
biomarkers with clinical outcomes in acute ischaemic stroke patients 
in RECAST-1 were assessed.
METHODS
Population
RECAST-1 was a pilot, single-centre, randomized, blinded, sham-con-
trolled trial in 26 patients with ischaemic stroke, who were randomized 
to receive four 5-min cycles of RIC or sham within 24 h of onset. The 
main results of the trial have been published: RIC was well tolerated, 
appeared safe and feasible in ischaemic stroke patients, and increased 
plasma HSP 27 [4]. In brief RECAST-1 recruited 26 adult patients from 
Derby Teaching Hospitals NHS Foundation Trust, UK, with ischaemic 
stroke within 24 h of ictus with arm and/or leg weakness. The interven-
tion comprised four cycles of intermittent upper limb ischaemia with 
5 min inflation 20 mmHg above the systolic blood pressure and 5 min 
deflation using a manual blood pressure cuff on the non-paretic arm. 
The sham group received cuff inflation to 30 mmHg only. The trial was 
registered (ISRCTN 86672015).
Blood samples
Venous blood samples were taken pre-intervention, immediately 
post-intervention and on day 4. These samples were centrifuged 
and the supernatant was stored at −80°C and later thawed for batch 
analysis. All biomarkers, except for NO, were analysed by enzyme-
linked immunosorbent assay.
Inflammation-related blood biomarkers
The MILLIPLEX panel (HCYTOMAG-60 K-08) was performed per the 
manufacturer’s instructions to detect changes in granulocyte colony-
stimulating factor (GCSF), interleukin-1α (IL-1α), IL-1β, IL-1 receptor an-
tagonist (RA), IL-6, IL-10 and tissue necrosis factor α (TNF-α) in plasma 
using the Luminex® xMAP® technology. HCVD3MAG-67 K-05 was 
used to detect adipsin, A2 M and SAP. E-selectin was measured using 
HCVD4MAG-67 K-02.
Neuroprotective and vascular blood biomarkers
Nitric oxide (NOx) in the form of nitrate (NO3−) and nitrite (NO2−) was 
measured in plasma samples using chemiluminescence (Sievers 280 
nitric oxide analyser, Analytix Ltd). Nitrate and nitrite are reduced to 
NO, which reacts with ozone to produce light detected by a sensi-
tive photomultiplier tube. NO analyser calibration was performed by 
injecting sodium nitrate standards ranging from 100 nM to 100 μM in 
concentration. Plasma samples, deproteinized with ethanol, were in-
jected in duplicate and the concentrations of plasma NOx were calcu-
lated from the calibration curve using the liquid programme installed 
on a dedicated laptop.
The MILLIPLEX panel (HCYTOMAG-60 K-08) also included mea-
suring VEGF-A in plasma using the Luminex® xMAP® technology 
as per the manufacturer's instructions. vWF was measured using 
HCVD3MAG-67 K-05.
Clinical outcomes
Clinical outcome measures were assessed at day 90: National 
Institutes of Health Stroke Scale (NIHSS), a measure of stroke sever-
ity; modified Rankin Scale (mRS), functional outcome; Barthel index 
(BI), a measure of disability; and the Mini-Mental State Examination 
(MMSE), a measure of cognition.
Statistics
The sample size for RECAST-1 was calculated for treatment toler-
ability: 26 participants were studied assuming a meaningful deliv-
ery of three of the four 5-min cycles of RIC with 90% power to 
reject the null hypothesis that intervention and sham were equally 
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tolerated. The present analyses are exploratory and hypothesis-
generating. Data are number (%), mean (standard deviation) and 
median (interquartile range). Baseline characteristics were com-
pared by chi-squared test, Kruskal–Wallis test or one-way ANOVA 
as appropriate. Changes in biomarkers over time were assessed 
using two-way ANOVA with resultant mean difference (MD) and 
95% confidence interval (CI). Biomarkers were correlated with clini-
cal outcomes at day 90 using Pearson's correlation coefficient. No 
adjustment was made for multiple testing. Significance was set at 
p < 0.05. Analyses were performed using SPSS version 24 and Prism 
version 7.
RESULTS
In total, 26 participants were recruited with a mean age of 76 
(10.5) years, 35% female, with moderate severity ischaemic strokes 
(NIHSS 6) and were randomized at 15.8 h after stroke onset. Bloods 
were taken before the intervention, immediately after and on day 
4. Baseline characteristics were well balanced between treat-
ment groups, although the sham group had more diabetes mellitus 
(Table 1).
Inflammation-related blood biomarkers
Serum amyloid protein levels reduced from pre- to post-intervention 
in those randomized to RIC (n = 13, two-way ANOVA, MD 10.47, 95% 
CI 0.30–20.64, p < 0.05) but did not in those randomized to sham 
(Figure 1). Levels of TNF-α also fell from pre- to post-intervention in 
those randomized to RIC (n = 13, two-way ANOVA, MD 3.58, 95% 
CI 0.40–6.77, p < 0.05). No significant changes over time, or by treat-
ment, were seen for adipsin, A2 M, GCSF-A or E-selectin (Figure 1).
IL-1RA, an immunomodulatory cytokine that inhibits the actions 
of IL-1α and IL-1β, fell from pre- to post-intervention in the sham 
group (n = 13, two-way ANOVA, MD 17.11, 95% CI 2.46–31.77, 
p < 0.05) but did not change in those randomized to RIC (Figure 2). 
No significant changes pre- to post-intervention or to day 4, or by 
treatment allocation, were seen for the other interleukins measured 
(Figure 2).
Neuroprotective and vascular blood biomarkers
Plasma NO, vWF or VEGF levels did not change over time or differ 





Patients 26 13 13
Age (years) 76.2 (10.5) 74.7 (10.8) 77.7 (10.4) 0.48
Sex, female 9 (34.6%) 5 (38.5%) 4 (30.8%) 0.68
Onset to randomization 
(h)
15.8 (6.2) 16.3 (5.9) 15.3 (6.6) 0.67
Systolic BP (mmHg) 159.2 (25.0) 153.7 (18.9) 164.7 (29.6) 0.27
Diastolic BP (mmHg) 82.9 (10.6) 81.5 (7.5) 84.3 (13.7) 0.53
Heart rate (bpm) 76.3 (15.2) 78.5 (13.1) 74.1 (17.3) 0.47
Premorbid mRS [/6] 0.0 [0.0, 1.0] 0.0 [0.0, 0.5] 0.0 [0.0, 2.0] 0.45
NIHSS [/42] 6 [3.7, 11] 6 [3.5, 12] 5 [3.9, 9.5] 0.72
TACS 8 (30.8%) 4 (30.8%) 4 (30.8%) 1.0
Past medical history
Hypertension 14 (53.8%) 5 (38.5%) 9 (69.2%) 0.12
Hyperlipidaemia 12 (46.2%) 5 (38.5%) 7 (53.8%) 0.43
Diabetes 5 (19.2%) 0 (0%) 5 (38.5%) 0.01
Atrial fibrillation 8 (30.8%) 3 (23.1%) 5 (38.5%) 0.40
Previous stroke 5 (19.2%) 1 (7.7%) 4 (30.8%) 0.14
Previous TIA 3 (11.5%) 2 (15.4%) 1 (7.7%) 0.54
Ischaemic heart 
disease
7 (26.9%) 2 (15.4%) 5 (38.5%) 0.19
Notes:: Comparison by chi-squared test, Kruskal–Wallis test or one-way ANOVA. Data are n (%), 
mean (standard deviation) or median [interquartile range].
Abbreviations: BP, blood pressure; bpm: beats per minute; mRS, modified Rankin Scale; NIHSS, 
National Institutes of Health Stroke Scale; RIC, remote ischaemic conditioning; TACS, total anterior 
circulation syndrome; TIA, transient ischaemic attack.
TA B L E  1  Baseline characteristics of 
RECAST-1 participants
4  |    APPLETON ET AL.
Association between absolute biomarker levels and 
clinical outcomes
Overall, higher S100-β levels at pre-intervention, post-inter-
vention and day 4 were significantly moderately correlated with 
worse NIHSS scores at day 90, but not mRS or BI (Table 2, Figure 
S1). Higher IL-1RA levels at day 4 were significantly moderately 
correlated with worse day 90 clinical outcomes (NIHSS, r = 0.410, 
p = 0.038; mRS, r = 0.455, p = 0.019; BI, r = −0.387, p = 0.051; 
Figure S2). Higher IL-6 levels post-intervention were significantly 
strongly correlated with improved day 90 clinical outcomes (mRS, 
r = −0.640, p = 0.025; BI, r = 0.651, p = 0.022); this correlation 
was mainly seen in those randomized to sham, not RIC (Tables 
S1 and S2). Inconsistently, higher IL-6 levels at day 4 were sig-
nificantly strongly correlated with worse NIHSS scores overall. 
Conversely, higher IL-10 levels at day 4 were significantly moder-
ately and strongly correlated with worse day 90 clinical outcomes 
(NIHSS, r = 0.702, p < 0.001; mRS, r = 0.493, p = 0.023; BI, −0.444, 
p = 0.044; Figure S2). No other consistently significant correla-
tions were noted for other biomarkers (Tables 2, S1 and S2).
F I G U R E  1  Effect of RIC on inflammation-related blood biomarkers. A2 M, alpha-2 macroglobulin; GCSF, granulocyte colony-stimulating 

















































































































F I G U R E  2  Effect of RIC on interleukins. IL, interleukin; IL-1RA, IL-1 receptor antagonist. *p < 0.05 between groups; #p < 0.05 in sham 














































































































    |  5BLOOD MARKERS IN RIC FOR ACUTE ISCHAEMIC STROKE
Association between change in biomarker levels and 
clinical outcomes
Overall, increases in SAP pre- to post-intervention and pre-interven-
tion to day 4 were significantly moderately correlated with worse day 
90 clinical outcomes (NIHSS, r = 0.400, p = 0.043; mRS, r = 0.505, 
p = 0.008; BI, r = −0.439, p = 0.025; MMSE, r = −0.395, p = 0.051; 
Table 3, Figure S3a,b). These significant correlations were seen in those 
randomized to sham but not in those randomized to RIC (Tables S3 and 
S4). Overall, an increase in A2 M pre-intervention to day 4 was weakly 
and moderately correlated with improved day 90 mRS (r = −0.359, 
p = 0.07) and MMSE (r = 0.465, p = 0.019) respectively. An increase 
in HSP 60 pre-intervention to day 4 was moderately and strongly 
correlated with worse clinical outcomes at day 90 (NIHSS, r = 0.641, 
p = 0.007; mRS, r = 0.500, p = 0.049; BI, r= −0.523, p = 0.038; Figure S4). 
Overall, an increase in IL-6 pre- to post-intervention was strongly cor-
related with improved clinical outcomes at day 90 (NIHSS, r = −0.584, 
p = 0.059; mRS, r = −0.677, p = 0.022; BI, r = 0.690, p = 0.019), which 
was mainly seen in those randomized to sham, not RIC (Tables S3 and 
S4). In contrast, an increase in IL-6 over 4 days was strongly correlated 
with worse NIHSS and non-significantly weakly correlated with worse 
mRS and BI. A similar picture was seen for IL-10 with increasing levels 
over 4 days being associated with a worse NIHSS (r = 0.592, p = 0.026). 
An increase in MMP-9 pre- to post-intervention was significantly mod-
erately correlated with worse clinical outcomes at day 90 (Figure S5); 
no such association was seen pre-intervention to day 4. An increase 
in S100-β pre-intervention to day 4 was moderately correlated with 
higher NIHSS scores at day 90. No significant correlations with out-
come were seen for adipsin, GCSF-A, E-selectin, TNF-α or other HSPs 
(Table 3).
An increase in NO levels pre-intervention to day 4 had a ten-
dency towards being weakly correlated with worse clinical outcomes 
at day 90 (NIHSS, r = 0.372, p = 0.062; mRS, r = 0.334, p = 0.10; 
BI, r = −0.355, p = 0.08, Table 3, Figure S6). Increases in VEGF lev-
els pre- to post-intervention and pre-intervention to day 4 were 
non-significantly weakly correlated with better clinical outcomes. 
No significant correlations were noted for vWF.
DISCUSSION
Here, in the first analysis assessing blood biomarkers in RIC in acute 
ischaemic stroke patients, it has been demonstrated that RIC re-
duced SAP and TNF-α levels. Overall, increasing SAP levels pre- to 
post-intervention and pre-intervention to day 4 were significantly 
moderately correlated with worse clinical outcomes after ischae-
mic stroke. Further, higher S100-β levels at pre-intervention, post-
intervention and day 4 were significantly moderately correlated with 
worse NIHSS scores at day 90. No other biomarkers had significant 
and consistent correlations with outcome at day 90.
In the primary RECAST-1 publication a significant increase in 
total and phosphorylated HSP 27 was reported in the RIC group, 
whilst other HSPs (60, 70) and C-reactive protein, S100-β, MMP-
9, troponin T and endocannabinoid levels did not differ between 
treatment groups [4]. These data are added to by demonstrating 
that RIC was associated with reductions in SAP and TNF-α pre- to 
post-intervention but did not influence other inflammatory cyto-
kines or putative neuroprotective biomarkers. The effect of RIC on 
reducing SAP and TNF-α was not maintained at day 4. This may indi-
cate that single four-cycle RIC might be insufficient to reduce these 
F I G U R E  3  Effect of RIC on neuroprotective and vascular blood biomarkers. NOx, nitrate/nitrite; vWF, von Willebrand factor; VEGF, 
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pro-inflammatory markers over a longer period. Whether repeated 
cycles of RIC over the first days prolong the reduction in these 
pro-inflammatory markers is a question for future studies.
In contrast to the present study, data from 50 healthy volun-
teers revealed that RIC was associated with elevated VEGF and 
four inflammation-related markers (transforming growth factor β1, 
leukaemia inhibitory factor, MMP-9 and tissue inhibitor of metal-
loproteinases 1) 1 h post-RIC [11]. These findings in healthy volun-
teers cannot be extrapolated to acute stroke patients. However, 
a recent study assessing RIC five times a week for 8 weeks after 
acute ischaemic stroke (post-conditioning) found that those who 
received RIC had lower levels of nuclear factor κB (an inflamma-
tory transcription factor) and toll-like receptor 4 (a mediator of 
systemic inflammatory response) and improved cerebral collat-
eral circulation scores on computed tomography angiography 
[12]. This anti-inflammatory effect of RIC was also seen in older 
patients with symptomatic intracranial arterial stenosis who re-
ceived 180 days of bilateral arm ischaemic preconditioning result-
ing in reduced markers of inflammation including highly sensitive 
C-reactive protein and IL-6 [13]. Here, it has been demonstrated 
that RIC administered as a one-off dose of four 5-min cycles of 
limb ischaemia may reduce some pro-inflammatory markers whilst 
promoting HSP 27 which may prevent breakdown of the blood–
brain barrier [14].
An increase in SAP from pre- to post-intervention and pre-in-
tervention to day 4 was associated with worse clinical outcomes at 
day 90, including cognition, across the trial population. SAP has an 
important role in inflammation and innate immunity, activating the 
classical complement pathway with increased SAP levels being asso-
ciated with increased death at day 90 after acute ischaemic stroke 
[6]. SAP binds to all forms of amyloid fibrils, is present in amyloid 
deposits and prevents proteolysis of the amyloid fibrils of Alzheimer 
disease [15]; its role in vascular cognitive impairment, however, is 
not well understood. Nonetheless, proof-of-concept studies of vas-
cular cognitive impairment and RIC demonstrate twice daily RIC for 
1 year improved visuospatial and executive function and reduced 
white matter hyperintensities compared with sham in a small study 
of 30 patients with cerebral small vessel disease [16]. One putative 
mechanism is that RIC reduces pro-inflammatory biomarkers (such 
as SAP), thereby improving vascular health and building ischaemic 
tolerance, resulting in improved clinical outcomes including cogni-
tion. Indeed, repeated RIC (or chronic RIC) has beneficial effects on 
vascular and endothelial function in healthy volunteers [17] and on 
cerebral blood flow after stroke caused by intracranial stenosis [18] 
and may be of therapeutic use in treating chronic inflammation asso-
ciated with atherosclerotic disease [19].
There was no difference in change in NO levels between those 
randomized to RIC vs. sham. This is in contrast to the human 
pre-clinical literature evaluating repeated RIC on blood flow, where 
it is apparent that RIC enhances peripheral endothelial function 
through an endothelium-dependent mechanism, which is inhibited 
by administration of an NO synthase inhibitor [10]. This does not 
necessarily mean that RIC does not influence NO levels in ischaemic 
stroke; it may suggest that the intervention occurred too late after 
stroke onset to influence NO levels, or repeated doses are needed, 
or the analyses are underpowered. In addition, NO has a very short 
half-life and so is challenging to measure. RIC has been assessed in 
other small studies involving ischaemic stroke patients within the 
thrombolysis window [20,21] in the context of mechanical throm-
bectomy [22] and in planned larger phase III efficacy trials including 
RECAST-3 (ISRCTN63231313) and Remote Ischemic Conditioning in 
Patients With Acute Stroke (RESIST, NCT03481777).
There are a number of limitations in our study. First, it was pow-
ered for tolerability of the intervention and not to detect changes in 
biomarkers; hence, the biomarker analyses may be underpowered. 
Further, the associations seen here may represent chance, perhaps 
in part due to multiple testing, and require confirmation in larger 
cohorts. In these exploratory and hypothesis-generating analyses, 
two putative biomarkers were positively influenced by RIC and re-
assuringly there were no concerning safety signals from this data-
set. Secondly, participants were recruited 16 h after stroke onset, 
which may be too late for RIC to exert any potential beneficial effect. 
Other studies have randomized patients in the hyperacute period 
and blood biomarker comparison with the present study may prove 
illuminating and instructive. Thirdly, RECAST-1 performed one set 
of four cycles of RIC and it is unclear how many cycles of RIC and 
over what time period are optimal; the following RECAST-2 trial ad-
dressed this [20]. Last, advanced imaging data are not available to 
quantify lesion size, which may have potentially influenced our find-
ings within or between treatment groups.
In summary, increases in plasma levels of SAP are associated with 
worse clinical outcomes after ischaemic stroke. RIC reduced SAP and 
TNF-α levels from pre- to post-intervention. These findings should 
be considered preliminary given the size of the study. Larger studies 
assessing biomarkers, safety and efficacy of RIC in acute ischaemic 
stroke are warranted; the RECAST-3 (ISRCTN63231313) and RESIST 
(NCT03481777) trials are addressing this question.
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